Neurent Medical, a company providing non-surgical interventions to treat chronic inflammatory sino-nasal diseases, today announced its NEUROMARK Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets.
Commercialization comes as the American Medical Association (AMA) issued a new Category I Current Procedural Terminology (CPT) code for posterior nasal nerve ablation (PNN) procedures, which includes NEUROMARK, to treat chronic rhinitis. The code will go into effect in January 2024. Furthermore, the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) endorses this procedure.
NEUROMARK’s device and intelligent technology platform enable Otolaryngologists to treat chronic rhinitis patients with precision and control and enhance the patient experience from treatment through recovery.
NEUROMARK is designed to apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This unique system offers ENTs a novel and unique leaflet design to help deliver precision neurolysis of posterior nasal nerves, with the intelligence and flexibility to comfortably accommodate a range of anatomies.
The recent endorsement of PNN by the AAO-HNS, a specialty society representing almost 12,000 ENT surgeons, further validates Neurent Medical’s long-term future in the treatment of chronic rhinitis.
